NEO100

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

10mo

NTHIPhase 2$183M

NEO100 Phase 2 Results Expected

NEO100• Residual, Progressive or Recurrent Grade II or III Meningioma30

Dec 30Estimated

00%

Competitive Landscape

0 competitors in Residual, Progressive or Recurrent Grade II or III Meningioma

Drug Information

Target Indication

Residual, Progressive or Recurrent Grade II or III Meningioma

Clinical Trial

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NTHI

NEONC TECHNOLOGIES HOLDINGS, INC.

Related Pipeline

Diffuse Astrocytoma, IDH-Mutant

Glioblastoma Multiforme